Actively Recruiting
Multi-Center Observational Study Evaluating Bearing nsPVA Embolization Particles for Treatment of Uterine Fibroids with Uterine Artery Embolization
Led by Merit Medical Systems, Inc. · Updated on 2026-10-07
100
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a prospective, multicenter observational study to follow up on patients treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. This study aims to collect data on the safety and performance of the Bearing nsPVA device in treating symptomatic uterine fibroids over a 6-month period after the procedure. Participants will have undergone uterine artery embolization using Bearing nsPVA Embolization Particles, which are specially designed polyvinyl alcohol particles used to block blood flow to uterine fibroids. The study observes outcomes without altering routine care and focuses on the devices effect in reducing blood flow to these fibroids. During the study, participants will be monitored for safety up to 30 days post-procedure and for treatment effectiveness through 6 months. Data collection includes assessments of safety events and performance outcomes related to the device, with no additional experimental treatments administered. The total participation duration is approximately 6 months following treatment.
CONDITIONS
Brief Title
Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)
Research Team
M
Molly Ryan
V
Vicky Brunk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here